Frontier Biotechnologies Inc., a commercial-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes various medicines that improve patients' health in China. It offers Aikening, an IV fusion inhibitor for dual therapy of HIV-1. The company's pipeline products include FB2004 indicated for HBV; FB7011 and FB7013 for IgA nephropathy; FB7012 to treat hyperuricemia and gout; FB7041 to treat tumors; FB7024 for the treatment of hyperlipidemia; FB7023 to treat ASCVD; FB7033 for the treatment of MASH; FB4001 for osteoporosis; and FB3002 for pain management. Frontier Biotechnologies Inc. was founded in 2002 and is headquartered in Nanjing, China.
Frequently asked questions
What sector does Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) operate in?
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) current stock price?
As of the latest data, Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A stock price is CN¥16.87, with a previous close of CN¥16.42. Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A gained CN¥0.45 in the last trading session, representing a 2.74% increase.
What is Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) current market capitalization?
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A market cap is approximately 6.32 billion.
What is Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) Earnings Per Share (EPS)?
The trailing EPS is -CN¥0.06, and the forward EPS is -CN¥0.75.
Does Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) pay dividends?
No. Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A does not pay a dividend.
What is Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A (688221) beta (volatility) score?
Frontier Biopharmaceuticals (Nanjing) Co. Ltd. A has a beta of 0.887, meaning its volatility is roughly in line with the market.
